Skip to main content

Table 6 Logistic regression analysis for minimum NIC of Grade 0 (Uncoverage) in patients with DM

From: Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation

 

Univariate

Multivariate

 

OR

95% CI

p value

OR

95% CI

p value

Male

1.09

0.39–3.30

1.00

   

Age

(1 year increase)

1.008

098-1.04

0.65

   

BMI

1.04

0.96–1.12

0.35

   

Hypertension

1.12

0.37–3.38

1.00

   

Dyslipidemia

2.01

0.82–5.14

0.14

   

Aspirin*

–

–

–

   

Clopidogrel*

1.01

0.51–2.02

1.00

   

Prasugrel*

1.15

0.58–2.32

0.72

   

Ticlopidine*

0.42

0.048–3.71

0.38

   

Statin*

2.11

0.94–4.72

0.088

2.44

1.01–5.87

0.047

Insulin, n (%)

0.82

0.32–2.11

0.82

   

Biguanide, n (%)

1.43

0.68–3.03

0.44

   

DPP-4 inhibitor, n (%)

1.36

0.68–2.74

0.48

   

SGLT-2 inhibitor, n (%)

0.53

0.058-4.90

0.50

   

Thiazolidine, n (%)

0.82

0.27–2.44

0.79

   

Sulfonylurea, n (%)

2.62

1.23–5.57

0.016

3.87

1.66–9.01

0.002

Glinide, n (%)

0.93

0.23–3.75

0.61

   

α-glucosidase inhibitor, n (%)

1.78

0.79–4.04

0.19

   

Follow-up duration

(1 day increase)

0.995

0.984–1.007

0.44

   

ACS

1.13

0.53–2.37

0.85

   

Pre-dilatation balloon maximum diameter

(1 mm increase)

1.09

0.63–1.90

0.76

   

Pre-dilatation balloon maximum inflation pressure

(1 atm increase)

1.06

0.96–1.16

0.28

   

Maximum stent diameter

(1 mm increase)

1.49

0.69–3.20

0.31

   

Minimum stent diameter

(1 mm increase)

1.13

0.50–2.53

0.77

   

Stent implantation pressure

(1 atm increase)

0.91

0.81–1.02

0.097

0.87

0.76–0.99

0.040

Post-dilatation balloon maximum diameter

(1 mm increase)

0.86

0.43–1.73

0.67

   

Post-dilatation balloon maximum inflation pressure

(1 mm increase)

0.94

0.84–1.05

0.26

   

At the time of PCI

      

HbA1c

(1% increase)

1.07

0.81–1.42

0.65

   

FBS

(1 mg/dL increase)

1.001

0.996–1.007

0.67

   

CRP

(1 mg/dL increase)

1.16

0.84–1.61

0.36

   

Total cholesterol

(1 mg/dL increase)

0.996

0.987–1.005

0.35

   

Triglyceride

(1 mg/dL increase)

1.000

0.997–1.003

0.85

   

HDL-cholesterol

(1 mg/dL increase)

1.022

0.994–1.050

0.12

   

LDL-cholesterol

(1 mg/dL increase)

0.989

0.978-1.000

0.056

0.984

0.972–0.997

0.018

At the time of CAS evaluation

      

HbA1c

(1% increase)

1.23

0.82–1.86

0.32

   

FBS

(1 mg/dL increase)

0.999

0.992–1.005

0.70

   

CRP

(1 mg/dL increase)

0.53

0.18–1.55

0.53

   

Total cholesterol

(1 mg/dL increase)

0.999

0.989–1.009

0.81

   

Triglyceride

(1 mg/dL increase)

1.002

0.999–1.005

0.13

   

HDL-cholesterol

(1 mg/dL increase)

1.001

0.982–1.021

0.91

   

LDL-cholesterol

(1 mg/dL increase)

0.990

0.977–1.004

0.17

   
  1. * Medication at the time of CAS evaluation. ACS acute coronary syndrome, BMI  body mass index, CRP C-reactive protein, DM diabetes mellitus, FBS  fasting blood sugar, HbA1c = Hemoglobin A1c, HDL high-density lipoprotein, LDL  low-density lipoprotein